A Phase 1, Open-label, Single Dose Study To Evaluate The Effects Of Food And The Proton Pump Inhibitor, Esomeprazole, On The Pharmacokinetics Of Crizotinib In A Coated Microsphere Formulation In Adult Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Crizotinib (Primary) ; Esomeprazole
- Indications Bladder cancer; Glioblastoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 27 Oct 2017 Status changed from active, no longer recruiting to completed.
- 08 Sep 2017 Planned primary completion date changed from 14 Sep 2017 to 17 Sep 2017.
- 08 Sep 2017 Status changed from recruiting to active, no longer recruiting.